NEWS HEADLINES PLUS

  Picture this: It’s 2018. A scrappy team in Hyderabad spots a massive headache for Indian factories—legacy servers choking on data, downtime bleeding crores, and zero real-time insights. They roll up sleeves, code a cloud-native beast, and Workmates Core2Cloud is born. Fast-forward to 2025: they’re powering AWS-tier digital transformation for 200+ enterprises, with a war-chest of ISO 27001, 9001, and 7 AWS competencies . Now, they’re hitting the NSE SME with a ₹69.84 Cr fresh issue —and you’re invited to the party. Whether you’re a first-time retail bidder staring at your phone or an HNI hunting the next Zoho , this guide is your human-to-human cheat sheet . No jargon salads. Just real talk, real numbers, and a clear path to apply before Nov 13 closes . Ready to ride the cloud wave? Open your free Demat with Upstox in 5 mins — zero AMC, UPI bids, done. Who Is Workmates Core2Cloud? (The Story Behind the Servers) Think of them as the "Digital Janitors" for India Inc....

  Namaste, fellow investor! If you're scouting for the next big splash in India's booming agrochemical wave, the Mahamaya Lifesciences IPO is your golden harvest. From a modest Punjab lab in 2002 to a powerhouse crafting crop-saving pesticides, Mahamaya is the unsung hero feeding India's ₹60,000 crore agrochem market (growing at 8% CAGR). Think fungicides, herbicides, and bulk formulations keeping farms pest-free and yields high. Launching November 11, 2025, this ₹70.44 crore fresh issue is all about fueling expansion—no OFS drama. Valued at ~₹250 crore pre-IPO, it's a bet on "Atmanirbhar Bharat" in chemicals. Retail warrior or HNI strategist? This heartfelt, no-BS guide walks you through. Ready to sow? Open a free Demat account with Upstox —paperless, quick, and your gateway to seamless IPO action. What is Mahamaya Lifesciences? A Quick Company Overview Rewind to 2002: A visionary team in Ludhiana sees farmers battling pests with pricey imports. Mahamaya ...

  Ever wondered how those razor-sharp tools slicing through metal in factories get made? Enter the Shing Tools Ltd IPO —a gritty, no-nonsense debut from a Bengaluru workshop that's quietly revolutionizing India's manufacturing backbone. If you're into SME stories that blend precision engineering with real-world grit, this one's for you. From carbide cutters to custom drills, Shing Tools crafts high-performance gear for auto giants, aerospace, and beyond. Kicking off November 12, 2025, this ₹73.80 crore fresh issue is your shot at backing a homegrown hero in the ₹50,000 crore Indian tooling market (sizzling at 15% CAGR). Valued at ~₹280 crore pre-IPO, it's all about scaling smart. Retail rookie or HNI pro? This guide's got the roadmap, minus the fluff. Pumped? Open a free Demat account with Upstox —zero hassle, full throttle for IPO bids. What is Shing Tools Ltd? A Quick Company Overview Flashback to 2015: A team of engineers in Bengaluru's buzzing industr...

 Hello Investors ,  If you're keeping tabs on the SME IPO frenzy this November, the Curls Lifesciences IPO is lighting up the charts like a breakthrough drug in a pharma trial. From a cozy Bengaluru lab to a powerhouse churning out life-saving injectables, Curls Lifesciences is the kind of under-the-radar story that could supercharge your portfolio. Think affordable meds for hospitals and clinics—antihistamines, antibiotics, and more—delivered with precision and pride. As of November 7, 2025, this pharma SME is set to raise ₹27.98 crore through a fresh issue, hitting NSE Emerge with a bang. Valued at around ₹100 crore pre-IPO, it's a bet on India's booming ₹4 lakh crore pharma manufacturing sector (growing at 12% CAGR). Whether you're dipping toes as a retail newbie or scaling up as an HNI, this no-fluff guide has your back. Feeling the pull? Open a free Demat account with Upstox —it's your ticket to easy IPO applications and beyond. What is Curls Lifesciences? A...

  If you're navigating the buzzing world of SME IPOs like me, the FinBud Financial Services IPO is one you won't want to miss. Launched in the heart of India's booming fintech scene, FinBud is making waves as a smart loan aggregator that's simplifying credit for everyday folks and small businesses. Imagine a platform that matches you with the perfect personal, business, or home loan—without the hassle of endless paperwork or high fees. That's FinBud in a nutshell. As we hit November 2025, this IPO is your chance to back a company that's grown from a Bengaluru startup to a key player in digital lending. Valued at around ₹200 crore pre-IPO, it's raising ₹71.68 crore entirely through fresh shares—no offer for sale here, meaning all funds fuel growth. Whether you're a first-time retail investor or a seasoned HNI, this guide breaks it down simply, with real insights to help you decide. Excited? Let's dive in. And if you're ready to apply, open a fre...